Philippines - English - FDA (Food And Drug Administration)

n/a; importer: n/a; distributor: one pharma marketing inc. - ascobic acid , zinc - capsule - 500 mg (equivalent to 562.4 mg sodium ascorbate)/ 10 mg (equivalent to 27.5 mg zinc sulfate monohydrate)

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: one pharma marketing inc.; distributor: one pharma marketing inc. - cilostazol - controlled-release tablet - 200 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: one pharma marketing inc.; distributor: one pharma marketing inc. - cilostazol - controlled-release tablet - 100 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: one pharma marketing inc.; distributor: one pharma marketing inc. - clindamycin (as phosphate) - solution for injection (i.m./i.v.) - 150 mg/ml

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: one pharma marketing inc.; distributor: one pharma marketing inc. - sildenafil (as citrate) - film-coated tablet - 50 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: one pharma marketing inc.; distributor: one pharma marketing inc. - carvedilol - tablet - 6.25 mg

Philippines - English - FDA (Food And Drug Administration)

synergen asia pte., ltd.; importer: synergen pharma inc.; distributor: one pharma marketing inc. - finasteride - tablet - 5 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: n/a; distributor: one pharma marketing inc. - glimepiride - tablet - 2 mg

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. - cardiogenic shock. - sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia leading to syncope without a functioning pacemaker. - known hypersensitivity to the drug or to any of its components, including iodine. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventric

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone hydrochloride 200 mg - amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. risk summary available data from postmarketing reports and published case series indicate that amiodarone use in pregnant women may increase the risk for fetal adverse effects including neonatal hypo- and hyperthyroidism, neonatal bradycardia, neurodevelopmental abnormalities, preterm birth and fetal growth restriction. amiodarone and its metabolite, desethylamiodarone (dea), cross the placenta. untreated underlying arrhythmias, including ventricular arrhythmias, during pregnancy pose a risk to the mother and fetus (see clinical considerations). in animal studies, administration of amiodarone to rabbits, rats, and mice during organogenesis resulted in embryo- fetal toxicity at dos